Gabapentin for Radiculopathy
Gabapentin is NOT recommended as a first-line treatment for radiculopathy, particularly lumbosacral radiculopathy, as it has consistently failed to demonstrate efficacy in high-quality trials and may be associated with small, transient benefits at best. 1
Evidence Against Gabapentin for Radiculopathy
The most compelling evidence comes from multiple guideline sources that explicitly identify lumbosacral radiculopathy as a neuropathic pain condition that is relatively refractory to gabapentinoids. The Mayo Clinic neuropathic pain guidelines specifically state that "recent trials of nortriptyline and morphine and their combination and pregabalin and an equivocal trial of topiramate suggest that lumbosacral radiculopathy might be a third peripheral NP condition that is relatively refractory to existing first- and second-line medications" 1. This pattern of negative trials suggests that efficacy demonstrated in other neuropathic conditions (like postherpetic neuralgia or diabetic neuropathy) cannot be extrapolated to radiculopathy.
The 2007 American College of Physicians/American Pain Society guideline notes that gabapentin is associated with only "small, short-term benefits" in patients with radiculopathy and has not been directly compared with other medications or treatments 2. Critically, neither gabapentin nor benzodiazepines are FDA-approved for treatment of low back pain with or without radiculopathy 2.
FDA-Approved Indications
The FDA label for gabapentin explicitly lists only two approved indications: management of postherpetic neuralgia in adults and adjunctive therapy for partial onset seizures 3. Radiculopathy is notably absent from approved indications, making any use for this condition off-label.
Clinical Trial Evidence
A 2015 multicenter randomized double-blind trial directly compared epidural steroid injection versus gabapentin for lumbosacral radicular pain and found no significant differences in the primary outcome (average leg pain at one and three months) 4. While epidural steroid injection showed some modest advantages in secondary outcomes at one month, these differences were transient and not sustained at three months.
More concerning, a 2026 retrospective cohort study of 23,379 matched patients found that gabapentin prescription for newly-diagnosed cervical radiculopathy was associated with significantly increased risks compared to NSAIDs, including: posterior cervical fusion (RR: 3.23), opioid-related disorder (RR: 2.87), opioid-related adverse events (RR: 2.32), and increased health service utilization 5. The study concluded that "no outcome favored gabapentin over NSAIDs."
Comparison with Pregabalin
Recent meta-analyses comparing gabapentin to pregabalin show that pregabalin may be slightly more effective than gabapentin for short-term pain reduction (≤6 weeks) in lumbar radiculopathy, though no difference exists at longer follow-up 6. However, this does not establish efficacy for either agent—it merely suggests pregabalin may be marginally less ineffective in the short term.
Alternative Recommendations
For diabetic peripheral neuropathy specifically (not radiculopathy), the 2021 American Diabetes Association guidelines recommend pregabalin, duloxetine, or gabapentin as initial pharmacologic treatments 7. However, this recommendation applies to diabetic neuropathy, not radiculopathy, and should not be extrapolated.
For HIV-associated neuropathic pain, the 2017 HIVMA/IDSA guideline recommends gabapentin as first-line therapy 8, but again, this is a distinct condition from mechanical radiculopathy.
Clinical Pitfalls
Common prescribing errors to avoid:
Do not assume efficacy in radiculopathy based on trials in postherpetic neuralgia or diabetic neuropathy—the evidence explicitly shows these conditions respond differently 1
Beware of insurance company requirements that mandate gabapentinoid trials before allowing duloxetine, as this contradicts guideline recommendations 9
Recognize the risk of opioid co-prescription—approximately 14% of patients are co-prescribed opioids at radiculopathy diagnosis, and gabapentin use is associated with increased opioid-related disorders 4, 5
Monitor for increased healthcare utilization—gabapentin prescription is associated with higher rates of surgical intervention and imaging compared to NSAIDs 5
Practical Algorithm
For acute/subacute radiculopathy (<6 weeks):
- First-line: NSAIDs, activity modification, physical therapy
- Consider: Short course of oral corticosteroids (though evidence is limited)
- Avoid: Routine gabapentin prescription
For chronic radiculopathy (>6 weeks) failing conservative management:
- Reassess diagnosis with MRI if not already performed
- Consider: Epidural steroid injection for targeted nerve root compression
- Pharmacologic options: Tricyclic antidepressants for chronic pain component
- Gabapentin may be considered as a third-line option only after failure of better-supported treatments, with realistic expectations of minimal benefit
If gabapentin is prescribed despite limited evidence:
- Target dose: 1800-3600 mg/day in divided doses (though even these doses show inconsistent benefit in radiculopathy)
- Time-limited trial: 4-6 weeks maximum
- Discontinue if no meaningful improvement
- Monitor for sedation, dizziness, and avoid concurrent opioid prescription
The weight of guideline evidence and clinical trial data does not support gabapentin as an appropriate first-line or even second-line treatment for radiculopathy, regardless of whether it involves cervical or lumbosacral nerve roots.